Topic

Articles

The new partnership hopes to increase funding and awareness of global health security challenges and highlight the role of the pharmaceutical industry in increasing access to medicines and improving health worldwide.

New Partnership Launched by Connect in Pharma for Global Health Innovation

Additionally, 89 human medicines have been recommended for approval by the EMA, and the organization also analyzed a new vaccine against dengue and two diabetes treatments that address important public health issues outside the EU.

EMA Executive Director Sends Message of Promoting Stronger Public Presence for Safety, Efficacy of Medicines

In addition, the Clinical Trials Regulation is set to become a single-entry point for sponsors and regulators in January 2023 for the submission and assessment of all new clinical trials.

Highlights of December 2022 EMA Management Board Meeting 

The first part of the 2021 CPhI Annual Report has been published and predicts a strong outlook for CDMOs over the next few years.

CPhI Reports Strong Outlook for Outsourced Services in Near Future

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Bio/pharmaceutical manufacturers have made a good first step toward global vaccination through pledging doses at no- to low-profit rates. 

A “We are the World” Vaccination Effort?

Shutting down the COVID-19 pandemic requires a global, selfless effort.

Ensuring Vaccine Supply Meets Global Needs

With the first announced drug shortage tied to the coronavirus outbreak, FDA emphasizes urgency for monitoring drug supply chain.

FDA Ties First Drug Shortage to Coronavirus Outbreak

Bio/pharma researchers mobilize to diagnose and treat patients in pandemic threat.

The Call for a Rapid Response

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

FDA’s approval rate slowed, but the US agency is still ahead of its international counterparts in green-lighting new drugs for market.

US Maintains Lead in Drug Development Despite Fewer Approvals in 2019

Agnes Shanley is senior editor of Pharmaceutical Technology.

Antimicrobial resistance is now the third leading cause of death in the US. As developers continue to leave an unprofitable market, legislation and new reimbursement models propose to stimulate development of new antibiotics.

Global Perspectives